Resonance Health posts record half-year revenue and returns to profit

Resonance Health Ltd ( (AU:RHT) ) has shared an update.

Resonance Health reported a 53% jump in half-year revenue to $8 million and returned to profitability with a $1.5 million net profit after tax, supported by positive operating cash flow and a 20% normalised EBITDA margin. Growth was driven across its clinical trial management services, the outperforming TrialsWest clinic network and increased SaMD usage, including new modalities like MRE and VAT & SAT measurements.

The company advanced major global pharmaceutical clinical trial contracts, expanded its forward SaMD order and bid pipeline to more than $10 million and completed key development milestones, including an extended proof-of-concept trial for a non-invasive MRI liver fibrosis device and testing of its Bridge automation technology. It is also pushing into large international markets, progressing discussions with healthcare providers in China and strengthening its presence in India with a dedicated business development manager to capture rising demand from global pharma customers.

The most recent analyst rating on (AU:RHT) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Resonance Health Ltd stock, see the AU:RHT Stock Forecast page.

More about Resonance Health Ltd

Resonance Health Ltd is an Australian medical technology company specialising in imaging-based diagnostics and services for clinical trials. Its core operations span clinical trial management through Resonance Clinical, a growing clinical trial site network under the TrialsWest brand, and software-as-a-medical-device (SaMD) image analysis products such as FerriScan and HepaFat, with expanding applications in metabolic, liver and oncology indications.

Average Trading Volume: 297,763

Technical Sentiment Signal: Hold

Current Market Cap: A$20.42M

For an in-depth examination of RHT stock, go to TipRanks’ Overview page.